Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. [electronic resource]
Producer: 20170804Description: 1174-80 p. digitalISSN:- 1528-0020
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Dexamethasone -- administration & dosage
- Disease-Free Survival
- Female
- Humans
- Lenalidomide
- Male
- Middle Aged
- Multiple Myeloma -- drug therapy
- Oligopeptides -- administration & dosage
- Recurrence
- Risk Factors
- Survival Rate
- Thalidomide -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.